Endocrinology Drugs Market- By Therapy Type , , By Chemical Structure , By Organ/Gland Targeted , By End Use Industry, By Distribution Channel , By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.

Endocrinology Drugs Market Overview:

Endocrinology Drugs Market size is estimated to reach $48 billion by 2030, growing at a CAGR of 7.8% during the forecast period 2024-2030. Endocrine drugs are medications used to treat conditions related to the endocrine system, a network of glands that produce hormones that regulate various bodily functions. These hormones travel through the bloodstream and signal specific organs and tissues to perform certain actions. Rising prevalence of endocrine disorders, growing geriatric population and the increasing investment in healthcare, are set to drive the growth of the global Endocrinology Drugs Market during the forecast period 2024-2030.  

The shift towards personalized medicine and the growing demand for telemedicine and remote monitoring are major trends influencing the growth of the endocrinology market. Personalized medicine is an emerging practice that uses an individual's genetic makeup, environment, and lifestyle to tailor medical treatments and prevention strategies. This approach has the potential to improve the effectiveness of treatment and reduce side effects. The rise of telemedicine and remote monitoring technologies allows for continuous patient management making it easier to adjust treatment plans based on real-time data. These trends are set to have a favorable impact on the outlook of the endocrinology drugs industry throughout the forecast period. 

Market Snapshot: 

Endocrinology Drugs Market- Report Coverage:

The “Endocrinology Drugs Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Endocrinology Drugs Market.

Impact of Covid and Russia Ukraine War:

The COVID-19 pandemic handicapped the global market extensively resulting in several challenges most notably, supply chain disruptions, but the pandemic caused an upsurge in the sales of the pharma industry. With increasing number of lifestyle diseases, there was a substantial demand for drugs during the pandemic, particularly diabetes medication. According to the American Diabetes Association, people with diabetes are more likely to have serious complications from COVID-19, especially if their diabetes is not well managed. Several online pharmacies experienced

record sales during the pandemic. 

The ongoing Ukraine-Russia conflict's impact on Endocrinology Drugs is indirect. Disruptions in supply chains due to the conflict led to delays in shipments of these drugs. Additionally, geopolitical tensions affect the manufacturing and distribution of the product, causing fluctuations in market availability, pricing, and international trade dynamics within the industry.

Key Takeaways:

North America is the largest Market

Geographically, North America held the largest share with 37% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. North America, particularly the United States, faces a high prevalence of conditions like diabetes, thyroid disorders, and obesity.  According to the CDC’s (Centers for Disease Control) National Diabetes Statistics Report for 2022, cases of diabetes have risen to an estimated 37.3 million.  11.3% of the U.S. population has diabetes. According to Diabetes Canada, every 3 minutes one person in Canada is diagnosed with diabetes. This underscores the importance of endocrinology drugs in this region. 

By Therapy Type, Diabetes is the largest Market

Diabetes is a global health crisis necessitating the use of insulin particularly in Type 1 diabetics. According to the IDF Annual Report 2022 prepared by the International Diabetes Federation (IDF), the number of people living with diabetes has more than 

tripled since 2000, from 151 million to 537 million people in 2021. With over 141 million people with diabetes, China accounts for one in four people with the condition 
worldwide. The increasing prevalence of diabetes drives the demand for endocrinology drugs including insulin and other glucose-lowering medications.

By Target Gland, Thyroid is expected to grow the fastest

Thyroid disease is a global health problem that can substantially impact well-being, particularly in pregnancy and childhood. In advanced economies, the prevalence of undiagnosed thyroid disease is falling owing to widespread thyroid function testing and relatively low thresholds for treatment initiation. According to NHS, Hypothyroidism, the most common thyroid disorder, typically requires lifelong hormone replacement therapy. This ongoing need for medication fuels market growth. According to a report of University of Aberdeen, one in 20 people in the UK have a thyroid problem, with women six times more likely to suffer from the condition than men.

Increase in Geriatric Population is Projected to Drive Market Growth

The geriatric population is predicted to reach 16% by 2050. US, Canada, Europe, India, and China are some regions where the geriatric population's growth is anticipated to witness rapid surges during the forecast period. For instance, with the decadal growth rate of the elderly population of India currently estimated to be at 41%, and the percentage of elderly population in the country projected to double to over 20% of total population by 2050, the United Nations Population Fund, India (UNFPA) in its 2023 India Ageing Report has said that by 2046 it is likely that elderly population will have surpassed the population of children (aged 0 to 15 years) in the country. The risk of diseases and disorders such as diabetes and cancer increase with age. The global diabetic population set to reach around 700 million by 2045, as per the International Diabetes Federation (IDF). Thus, the increase in the geriatric population is set to drive the endocrine drugs market.

Stringent Regulations

Stringent regulations in the Endocrinology Drugs market can delay access to new medications, especially for critical conditions. The thorough testing and evaluation required by regulatory agencies like the US Food and Drug Administration (FDA) can significantly delay the availability of new Endocrinology Drugs to patients.  Compliance with these regulations involves extensive documentation, testing, and validation processes, which can be time-consuming and resource-intensive for manufacturers. Any deviation from regulatory requirements can result in delays, fines, or even product recalls, impacting market entry and business operations. Moreover, staying updated with evolving regulatory frameworks adds complexity to the process, further straining resources and hindering market access for both new entrants and established players.

Endocrinology Drugs Market: Market Share (%) by Region, 2023     

       For More Details on This Report - Request for Sample

Key Market Players: 

The top 10 companies in the Endocrinology Drugs Market are:

1. Johnson & Johnson
2. Novo Nordisk A/S
3. F. Hoffmann-La Roche AG
4. GSK plc
5. Pfizer Inc.
6. Abbvie Inc.
7. Bayer AG
8. Sanofi S.A. 
9. Astrazeneca plc
10. Novartis AG  

For more Lifesciences and Healthcare Market reports, please click here